Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237551 | 0.90 | GAA (0.58) | GAADRD4DRD2DRD3ATM | |
| SCHEMBL17445905 | 0.80 | ATM (0.60) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL18235025 | 0.80 | DRD4 (0.57) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL6746156 | 0.80 | GAA (0.47) | GAAALDH1A1PDE3BPDE3AP2RY12 | |
| SCHEMBL6968933 | 0.80 | DRD2 (0.53) | GAADRD4DRD2DRD3L3MBTL1 | |
| SCHEMBL14844426 | 0.80 | LTA4H (0.53) | GAADRD4DRD2DRD3LTA4H | |
| SCHEMBL21051892 | 0.80 | DRD4 (0.46) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL27559192 | 0.79 | GAA (0.46) | GAAATML3MBTL1PDE3BPDE3A | |
| SCHEMBL7501215 | 0.79 | KCNA3 (0.62) | GAADRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL14844393 | 0.78 | GAA (0.46) | GAAL3MBTL1PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117731658-A | Japanese encephalitis virus inhibitor | 北京凯因格领生物技术有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-113861176-B | A flavivirus inhibitor | 北京凯因格领生物技术有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4100009-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2020163244-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2018-02-08 | — | — | US | disclosed |
| EP-3267983-A1 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145046-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | GAA 125/4885DRD4 3037/4885DRD2 2315/4885 |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GAA 3/4885DRD4 4878/4885DRD2 4837/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | GAA 5/4885DRD4 3564/4885DRD2 2743/4885 |
| US-20200197374-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | GAA 61/4885DRD4 1265/4885DRD2 1683/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GAA 3/4885DRD4 4878/4885DRD2 4837/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | GAA 4/4885DRD4 4873/4885DRD2 4849/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | GAA 3/4885DRD4 4878/4885DRD2 4837/4885 |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | GAA 61/4885DRD4 1265/4885DRD2 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.